Cargando…

Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas

SIMPLE SUMMARY: Epstein-Barr virus (EBV) is the first-discovered and important human tumor virus. It infects more than 90% of human population and induces various lymphomas. Development of specific targeted therapies is very critical for treatment of EBV-induced lymphomas, but it remains a great cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Yonggang, Wong, Josiah H. Y., Robertson, Erle S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564798/
https://www.ncbi.nlm.nih.gov/pubmed/32916819
http://dx.doi.org/10.3390/cancers12092565
_version_ 1783595796366622720
author Pei, Yonggang
Wong, Josiah H. Y.
Robertson, Erle S.
author_facet Pei, Yonggang
Wong, Josiah H. Y.
Robertson, Erle S.
author_sort Pei, Yonggang
collection PubMed
description SIMPLE SUMMARY: Epstein-Barr virus (EBV) is the first-discovered and important human tumor virus. It infects more than 90% of human population and induces various lymphomas. Development of specific targeted therapies is very critical for treatment of EBV-induced lymphomas, but it remains a great challenge. In this review, we introduced the current progress of EBV-specific therapies and the promising approaches that can be developed as novel targeted therapies, which involve protective or therapeutic strategies to target these lymphomas on different levels. This work will provide new insights into the development of new targeted therapies against EBV-associated lymphomas. ABSTRACT: The Epstein-Barr virus (EBV) is the first human tumor virus identified that can transform quiescent B lymphocytes into lymphoblastoid cell lines (LCLs) in vitro. EBV can establish asymptomatic life-long persistence and is associated with multiple human malignancies, including non-Hodgkin lymphoma and Hodgkin lymphoma, as well as infectious mononucleosis. Although EBV-associated lymphomagenesis has been investigated for over 50 years, viral-mediated transformation is not completely understood, and the development of EBV-specific therapeutic strategies to treat the associated cancers is still a major challenge. However, the rapid development of several novel therapies offers exciting possibilities to target EBV-induced lymphomas. This review highlights targeted therapies with potential for treating EBV-associated lymphomas, including small molecule inhibitors, immunotherapy, cell therapy, preventative and therapeutic vaccines, and other potent approaches, which are novel strategies for controlling, preventing, and treating these viral-induced malignances.
format Online
Article
Text
id pubmed-7564798
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75647982020-10-26 Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas Pei, Yonggang Wong, Josiah H. Y. Robertson, Erle S. Cancers (Basel) Review SIMPLE SUMMARY: Epstein-Barr virus (EBV) is the first-discovered and important human tumor virus. It infects more than 90% of human population and induces various lymphomas. Development of specific targeted therapies is very critical for treatment of EBV-induced lymphomas, but it remains a great challenge. In this review, we introduced the current progress of EBV-specific therapies and the promising approaches that can be developed as novel targeted therapies, which involve protective or therapeutic strategies to target these lymphomas on different levels. This work will provide new insights into the development of new targeted therapies against EBV-associated lymphomas. ABSTRACT: The Epstein-Barr virus (EBV) is the first human tumor virus identified that can transform quiescent B lymphocytes into lymphoblastoid cell lines (LCLs) in vitro. EBV can establish asymptomatic life-long persistence and is associated with multiple human malignancies, including non-Hodgkin lymphoma and Hodgkin lymphoma, as well as infectious mononucleosis. Although EBV-associated lymphomagenesis has been investigated for over 50 years, viral-mediated transformation is not completely understood, and the development of EBV-specific therapeutic strategies to treat the associated cancers is still a major challenge. However, the rapid development of several novel therapies offers exciting possibilities to target EBV-induced lymphomas. This review highlights targeted therapies with potential for treating EBV-associated lymphomas, including small molecule inhibitors, immunotherapy, cell therapy, preventative and therapeutic vaccines, and other potent approaches, which are novel strategies for controlling, preventing, and treating these viral-induced malignances. MDPI 2020-09-09 /pmc/articles/PMC7564798/ /pubmed/32916819 http://dx.doi.org/10.3390/cancers12092565 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pei, Yonggang
Wong, Josiah H. Y.
Robertson, Erle S.
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
title Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
title_full Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
title_fullStr Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
title_full_unstemmed Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
title_short Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
title_sort targeted therapies for epstein-barr virus-associated lymphomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564798/
https://www.ncbi.nlm.nih.gov/pubmed/32916819
http://dx.doi.org/10.3390/cancers12092565
work_keys_str_mv AT peiyonggang targetedtherapiesforepsteinbarrvirusassociatedlymphomas
AT wongjosiahhy targetedtherapiesforepsteinbarrvirusassociatedlymphomas
AT robertsonerles targetedtherapiesforepsteinbarrvirusassociatedlymphomas